Research programme: monoclonal antibody-based therapeutics - Compugen

Drug Profile

Research programme: monoclonal antibody-based therapeutics - Compugen

Alternative Names: Antibody-based cancer immunotherapies - Compugen; Cancer immunotherapies - Compugen; CGEN 15027-targeted mAb; CGEN 15027-targeted monoclonal antibody; CGEN 15052-targeted mAb; CGEN 15052-targeted monoclonal antibody; CGEN 15137-targeted antibody; CGEN 15137/TIGIT; CGEN 671-targeted mAb; CGEN 671-targeted monoclonal antibody; CGEN XXXX; CGEN-15001T-targeted mAb; CGEN-15001T-targeted monoclonal antibody; CGEN-15022-targeted mAb; CGEN-15022-targeted monoclonal antibody; CGEN-15049-targeted mAb; CGEN-15049-targeted monclonal antibody; CGEN-928-targeted mAb; CGEN-928-targeted monoclonal antibody; Immune checkpoint-targeted monoclonal antibodies - Compugen; Splice variant-targeted monoclonal antibody therapeutics - Compugen

Latest Information Update: 12 Feb 2015

Price : $50

At a glance

  • Originator Compugen
  • Class Monoclonal antibodies
  • Mechanism of Action B7 antigen inhibitors; CD28 antigen inhibitors; Immunomodulators; Membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours
  • Research Haematological malignancies; Malignant melanoma; Multiple myeloma

Most Recent Events

  • 18 Dec 2014 Compugen and Johns Hopkins University School of Medicine enter into a collaboration for evaluation of B7/CD28-like immune checkpoint candidates
  • 01 Oct 2014 Preclinical trials in Solid tumours in USA and Israel (Parenteral)
  • 01 Oct 2014 Pharmacodynamics data from a preclinical study in Solid tumours released by Compugen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top